Pharmacy/Rx Drugs

Legislation/IssuesSynopsisResourcesNew This Week/Upcoming Dates
SB 615 (HB 819) - Pharmacy Benefits Managers - Prohibited Actions Prohibiting a pharmacy benefits manager from engaging in any practice that bases certain reimbursement for a prescription drug on patient outcomes, scores, or metrics under certain circumstances; prohibiting a pharmacy benefits manager from engaging in the practice of spread pricing; prohibiting a pharmacy benefits manager from denying any pharmacy a certain right; prohibiting a pharmacy benefits manager from taking more than 30 days to review the application of a pharmacy or pharmacist to participate in a certain policy or contract; etc. SB 615

HB 819

Hearing 2/24 at 1:00 p.m. (1/31)

Hearing 2/10 at 1:30 p.m. (2/2)
HB 14 - Pharmacists - Prescription Drug and Device Labels - Expiration Dates Altering the expiration date that is required to be included, except under certain circumstances, on labels on drugs and devices dispensed in the manufacturer's original packaging by a pharmacist to the expiration date set by the manufacturer or a shorter period determined by the pharmacist. HB 14

Enacted under Article II, Section 17(c) of the Maryland Constitution - Chapter 489 (5/30)
HB 162 - Prescription Drug Affordability Board - Upper Payment Limits and Reports Altering a certain requirement that the Prescription Drug Affordability Board, in conjunction with a certain council, draft a certain plan for setting upper payment limits for prescription drug products; altering the date by which the Board is required to submit the plan to a certain committee of the General Assembly; requiring, rather than authorizing, the Board to set upper payment limits for certain prescription drug products and altering the date by which the limits are to be set to on or after February 1, 2022; etc. HB 162

Hearing 1/27 at 1:30 p.m. (12/23)
HB 1034 - Prescription Drug Affordability Board - Plan of Action - Repeal of Date for Submission Repealing the date by which the Prescription Drug Affordability Board is required to submit a certain plan of action regarding the establishment of a process for setting the upper payment limits for certain prescription drug products to the Legislative Policy Committee of the General Assembly. HB 1034

Enacted under Article II, Section 17(c) of the Maryland Constitution - Chapter 464 (5/30)
HB 1125 - Prescription Drug Monitoring Program - Prescribers of Opioids - Notification Requirement Requiring a prescriber to notify the Prescription Drug Monitoring Program as to whether the prescriber has received education regarding the risks of opioid use, is aware that an opioid overdose reversal drug is available, and has prescribed or dispensed an opioid overdose reversal drug if the prescriber prescribes or dispenses an opioid in a dosage of 50 morphine milligram equivalents or more; and prohibiting a prescriber from being required to make a certain notification more than once. HB 1125

Hearing 3/04 at 1:30 p.m. (2/11)